Elecoglipron and dapagliflozin together for adults with type 2 diabetes
Tests elecoglipron with dapagliflozin, versus each alone, in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Key facts
- Where
- Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng, Hangzhou, Hefei, Huai'an, Jinan, Jincheng, Jining, Jinzhou Shi, Kaifeng, Langfang, Liangyugang, Luoyang, Meihekou, Nanjing, Nantong, Nanyang, Pinggu, Pingxiang, Sanya, Shanghai, Shantou, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuhu, Xi'an, Xiangyang, Xianyang, Xuzhou, Yan’an, Yueyang, Zhumadian, and Zibo, ChinaSee the 41 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled by lifestyle changes alone or with other stable diabetes medicine.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes diagnosed at least 90 days before screening. HbA1c from 7% (53 mmol/mol) to 10.5% (53 to 91.3 mmol/mol). Blood sugar not well managed by lifestyle alone or by stable background diabetes medicine.
- Earlier treatment
- People are on lifestyle management alone or on stable treatment with other glucose-lowering medicine. Body weight must have been stable for 90 days before screening.
- Biomarker or test result
- HbA1c of 7% (53 mmol/mol) to 10.5% (53 to 91.3 mmol/mol). Body mass index (BMI) of 23 kg/m2 or more.
Main reasons for not taking part
- Type 1 diabetes, other secondary forms of diabetes, or a history of ketoacidosis or hyperosmolar coma
- More than one episode of severe low blood sugar in the 180 days before screening, or not noticing low blood sugar symptoms
- History of acute or chronic pancreatitis
- Severe heart failure (New York Heart Association IV)
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Read by machine on 9 November 2026.
Where in China
- BaotouBaotou, ChinaNot yet recruiting
- BeijingBeijing, ChinaTaking people
- ChangdeChangde, ChinaNot yet recruiting
- ChangshaChangsha, ChinaTaking people
- ChangzhouChangzhou, ChinaNot yet recruiting
- ChengduChengdu, ChinaNot yet recruiting
- ChenzhouChenzhou, ChinaNot yet recruiting
- ChifengChifeng, ChinaNot yet recruiting
- HangzhouHangzhou, ChinaNot yet recruiting
- HefeiHefei, ChinaTaking people
- Huai'anHuai'an, ChinaTaking people
- JinanJinan, ChinaTaking people
- JinchengJincheng, ChinaTaking people
- JiningJining, ChinaNot yet recruiting
- Jinzhou ShiJinzhou Shi, ChinaTaking people
- KaifengKaifeng, ChinaTaking people
- LangfangLangfang, ChinaNot yet recruiting
- LiangyugangLiangyugang, ChinaNot yet recruiting
- LuoyangLuoyang, ChinaNot yet recruiting
- MeihekouMeihekou, ChinaNot yet recruiting
- NanjingNanjing, ChinaNot yet recruiting
- NantongNantong, ChinaNot yet recruiting
- NanyangNanyang, ChinaTaking people
- PingguPinggu, ChinaTaking people
- PingxiangPingxiang, ChinaNot yet recruiting
- SanyaSanya, ChinaNo longer taking part
- ShanghaiShanghai, ChinaNot yet recruiting
- ShantouShantou, ChinaNot yet recruiting
- ShenyangShenyang, ChinaNot yet recruiting
- ShijiazhuangShijiazhuang, ChinaNot yet recruiting
- TianjinTianjin, ChinaNot yet recruiting
- WuhanWuhan, ChinaNot yet recruiting
- WuhuWuhu, ChinaTaking people
- Xi'anXi'an, ChinaNot yet recruiting
- XiangyangXiangyang, ChinaNot yet recruiting
- XianyangXianyang, ChinaNot yet recruiting
- XuzhouXuzhou, ChinaNot yet recruiting
- Yan’anYan’an, ChinaNot yet recruiting
- YueyangYueyang, ChinaNot yet recruiting
- ZhumadianZhumadian, ChinaTaking people
- ZiboZibo, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662109EU 2025-523941-81-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.Read full original descriptionShow less
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Inclusion: Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening; T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication; HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol); Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (New York Heart Association IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.